{{Rsnum
|rsid=1367117
|Gene=APOB
|Chromosome=2
|position=21041028
|Orientation=plus
|GMAF=0.2052
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=APOB
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 11.6 | 43.8 | 44.6
| HCB | 0.7 | 16.2 | 83.1
| JPT | 0.9 | 15.0 | 84.1
| YRI | 0.7 | 12.9 | 86.4
| ASW | 3.5 | 28.1 | 68.4
| CHB | 0.7 | 16.2 | 83.1
| CHD | 4.6 | 19.4 | 75.9
| GIH | 3.0 | 18.8 | 78.2
| LWK | 0.0 | 13.8 | 86.2
| MEX | 7.0 | 40.4 | 52.6
| MKK | 0.6 | 17.3 | 82.1
| TSI | 5.9 | 45.5 | 48.5
| HapMapRevision=28
}}[[rs1367117]] (C711T/711C>T) is a SNP within [[APOB]] (Apolipoprotein B).

{{PMID|15453913|OA=1
}} among 97 hypertensive subjects, C allele carriers responded to [[irbesartan]] with an average blood pressure reduction of 19 mmHg, however, they did not respond to [[atenolol]]

{{PMID|19888660|OA=1
}} associated with apoB levels

{{PharmGKB
|RSID=rs1367117
|Name_s=APOB:711C>T,
|Gene_s=APOB
|Feature=Exon/NonSyn
|Evidence=PubMed ID:15453913
|Annotation=The APOB:711C>T, C allele was associated with reduction of blood pressure in response to irbesartan treatment but not atenolol treatment.
|Drugs=atenolol; irbesartan
|Drug Classes=
|Diseases=Hypertension
|Curation Level=Curated
|PharmGKB Accession ID=PA162361480
}}

{{omim
|id=107730
|rsnum=1367117
}}

{{PMID Auto GWAS
|PMID=20686565
|Trait=None
|Title=Biological, clinical and population relevance of 95 loci for blood lipids.
|RiskAllele=A
|Pval=0
|OR=4.1600
|ORtxt=None
|OA=1
}}

{{PMID Auto
|PMID=16642433
|Title=Polymorphism in maternal LRP8 gene is associated with fetal growth.
|OA=1
}}

{{PMID Auto
|PMID=18078817
|Title=Multiple genetic determinants of plasma lipid levels in Caribbean Hispanics.
|OA=1
}}

{{PMID Auto
|PMID=18296645
|Title=Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China.
|OA=1
}}

{{PMID Auto
|PMID=18513389
|Title=New application of intelligent agents in sporadic amyotrophic lateral sclerosis identifies unexpected specific genetic background.
|OA=1
}}

{{PMID Auto
|PMID=19131662
|Title=A meta-analysis of candidate gene polymorphisms and ischemic stroke in 6 study populations: association of lymphotoxin-alpha in nonhypertensive patients.
|OA=1
}}

{{PMID Auto
|PMID=19263529
|Title=Genetic risk factors in recurrent venous thromboembolism: A multilocus, population-based, prospective approach.
|OA=1
}}

{{PMID Auto
|PMID=20832063
|Title=Exploring genetic determinants of plasma total cholesterol levels and their predictive value in a longitudinal study.
}}

{{GET Evidence
|gene=APOB
|aa_change=Thr98Ile
|aa_change_short=T98I
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1367117
|overall_frequency_n=2653
|overall_frequency_d=10758
|overall_frequency=0.246607
|n_genomes=15
|n_genomes_annotated=0
|n_haplomes=16
|n_articles=2
|n_articles_annotated=2
|gene_in_genetests=Y
|in_pharmgkb=Y
|genetests_testable=Y
|nblosum100=3
|autoscore=3
|webscore=N
|n_web_uneval=2
|summary_short=Irbestartan more effective than atenolol in lowering blood pressure.
}}

{{PMID Auto
|PMID=23298194
|Title=Epistatic study reveals two genetic interactions in blood pressure regulation
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}